Detalhe da pesquisa
1.
Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma-a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology.
Lancet Oncol
; 25(5): e193-e204, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38697165
2.
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
Lancet
; 402(10397): 185-195, 2023 07 15.
Artigo
Inglês
| MEDLINE | ID: mdl-37290461
3.
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
N Engl J Med
; 384(14): 1289-1300, 2021 04 08.
Artigo
Inglês
| MEDLINE | ID: mdl-33616314
4.
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 24(10): 1094-1108, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37714168
5.
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.
Lancet
; 400(10358): 1103-1116, 2022 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36099926
6.
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
J Transl Med
; 21(1): 75, 2023 02 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36737752
7.
Current Status of Predictive Biomarker Development in Metastatic Renal Cell Carcinoma.
Curr Oncol Rep
; 25(6): 671-677, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-37000341
8.
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a).
Int J Mol Sci
; 24(2)2023 Jan 06.
Artigo
Inglês
| MEDLINE | ID: mdl-36674615
9.
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(3): 393-405, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-35157830
10.
The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs.
J Transl Med
; 20(1): 371, 2022 08 16.
Artigo
Inglês
| MEDLINE | ID: mdl-35974365
11.
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study.
J Transl Med
; 20(1): 435, 2022 09 30.
Artigo
Inglês
| MEDLINE | ID: mdl-36180954
12.
SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM).
Radiol Med
; 127(5): 534-542, 2022 May.
Artigo
Inglês
| MEDLINE | ID: mdl-35303246
13.
Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators.
J Transl Med
; 19(1): 328, 2021 08 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34344414
14.
Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16).
Oncology
; 99(12): 747-755, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34583356
15.
Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinib.
BJU Int
; 128(2): 254-261, 2021 08.
Artigo
Inglês
| MEDLINE | ID: mdl-33547860
16.
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients.
Future Oncol
; 17(9): 1097-1104, 2021 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-33538178
17.
An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study.
Jpn J Clin Oncol
; 51(3): 484-491, 2021 Mar 03.
Artigo
Inglês
| MEDLINE | ID: mdl-33212499
18.
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
Cancer
; 126(18): 4156-4167, 2020 09 15.
Artigo
Inglês
| MEDLINE | ID: mdl-32673417
19.
Current Understanding of Urachal Adenocarcinoma and Management Strategy.
Curr Oncol Rep
; 22(1): 9, 2020 Jan 27.
Artigo
Inglês
| MEDLINE | ID: mdl-31989430
20.
Analysis of Single Circulating Tumor Cells in Renal Cell Carcinoma Reveals Phenotypic Heterogeneity and Genomic Alterations Related to Progression.
Int J Mol Sci
; 21(4)2020 Feb 21.
Artigo
Inglês
| MEDLINE | ID: mdl-32098246